Product image of Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone / Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular, subcutaneous use. It treats anovulation and supports ovarian stimulation in assisted reproductive technology in women. It is indicated for induction of ovulation in women with anovulatory disorders and for controlled ovarian stimulation during in‑vitro fertilisation cycles.
GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance through reliable cold‑chain logistics.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Meriofert, a gonadotropin used in reproductive medicine, is indicated for:
  • Anovulation: Induces ovulation in women who do not ovulate spontaneously.
  • Polycystic ovary syndrome (PCOS): Facilitates follicular growth and ovulation in PCOS patients.
  • Assisted reproductive technology (IVF): Provides controlled ovarian stimulation to generate multiple mature follicles for egg retrieval.

How It Works

  • Meriofert contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH). The FSH component binds to FSH receptors on ovarian granulosa cells, promoting follicular development and estrogen synthesis. LH binds to LH receptors on theca cells, stimulating androgen production that is aromatized to estrogen. Together they replicate the natural pituitary signal, driving follicle maturation and triggering ovulation. The combined activity enhances the hormonal milieu required for successful oocyte maturation.

Side Effects

Adverse reactions to Meriofert may vary in frequency and severity.

Common Side Effects

  • Injection site pain
  • Abdominal bloating
  • Nausea
  • Mild ovarian hyperstimulation

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome
  • Multiple pregnancy
  • Ovarian torsion
  • Anaphylactic reaction

Precautions & Warnings

  • When using Meriofert, clinicians should observe several precautionary measures to minimise risks.
  • Pregnancy testing: Verify that the patient is not pregnant before initiating therapy.
  • Ovarian monitoring: Perform serial ultrasound examinations to assess follicular response.
  • Risk of OHSS: Use the lowest effective dose and monitor estradiol levels to detect early signs.
  • Multiple gestation risk: Counsel patients about the increased chance of twins or higher-order pregnancies.
  • Allergy assessment: Screen for hypersensitivity to gonadotropin preparations.
  • Store at 2-8°C: Keep refrigerated, protect from light, and avoid freezing or shaking.

Avoid Interactions

Meriofert can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • GnRH antagonists: May blunt the ovarian response to FSH/LH.
  • Oral estrogen‑containing contraceptives: Can suppress endogenous gonadotropin activity.
  • Chemotherapy agents: May impair ovarian function and reduce effectiveness.
  • Concurrent use of other gonadotropins: Increases risk of ovarian hyperstimulation.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone replacement: May affect ovarian responsiveness; monitor thyroid status.
  • Glucocorticoids: Can mask early symptoms of OHSS; observe patient closely.
  • Anticoagulants: Monitor injection sites for prolonged bleeding.

Frequently Asked Questions

Meriofert contains follicle‑stimulating hormone and luteinising hormone and is used to induce ovulation in women who do not ovulate spontaneously. It is also employed to stimulate the ovaries during assisted reproductive technologies such as in‑vitro fertilisation, helping develop multiple follicles and supporting estrogen production for successful egg retrieval.

FSH binds to receptors on ovarian granulosa cells, promoting follicular growth and estrogen synthesis. LH binds to receptors on theca cells, stimulating androgen production that is converted to estrogen. The combined action mimics the natural pituitary signal, driving follicle maturation and ultimately triggering ovulation.

The dose of Meriofert is individualized by the prescribing physician based on the patient’s ovarian response, body weight, and treatment protocol. The prescriber determines the amount, frequency, and duration of administration, and may adjust the regimen according to monitoring results and clinical response.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT